In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...
Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health Administration: A single-center experience. This is an ASCO Meeting Abstract from ...
Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...
Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study. Results of a ...
Findings showed darolutamide reduced the risk of radiographic progression or death by 46% compared with placebo. The Food and Drug Administration (FDA) has approved Nubeqa ® (darolutamide), an ...
Verywell Health on MSN
Symptoms of metastatic castration-resistant prostate cancer
Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced ...
Stocktwits on MSN
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses
An exposure-response analysis showed a statistically significant link between higher drug exposure and increased toxicities ...
Transdermal oestradiol patches are non-inferior to luteinising hormone-releasing hormone agonists for metastasis free survival in locally advanced prostate cancer, a study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results